Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

This report provides an overview of the pipeline landscape for depression and anxiety disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD) and depression, and features dormant and discontinued products.

PTSD is a mental health condition that is triggered by either experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants and cognitive therapy. There are 38 products in development for this indication.

OCD is characterized by unreasonable thoughts and fears (obsessions) that lead to repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Treatment includes antidepressants and psychiatric medications. There are nine products in development for this indication.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers and antipsychotics. There are 212 products in development for this indication.

Molecular targets acted on by products in development for depression and anxiety disorders include neurotransmitter receptors such as glutamate receptors and 5-hydroxytryptamine receptors. Companies operating in this pipeline space include NeuroRx, Amorsa Therapeutics and Johnson & Johnson.

Scope

– Which companies are the most active within each pipeline?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Companies mentioned

Acadia Pharmaceuticals Inc

Ache Laboratorios Farmaceuticos SA

Actinogen Medical Ltd

Adamed Sp z oo

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

Albany Molecular Research Inc

Alkermes Plc

Allergan Plc

Amorsa Therapeutics Inc

Anavex Life Sciences Corp

Aptinyx Inc

Avanir Pharmaceuticals Inc

Axsome Therapeutics Inc

Azevan Pharmaceuticals Inc

BioCrea GmbH

Biohaven Pharmaceutical Holding Company Ltd

Bionomics Ltd

BioXcel Therapeutics Inc

Blackthorn Therapeutics Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Calico LLC

Catalyst Pharmaceuticals Inc

Celgene Corp

Cellix Bio Pvt Ltd

Celon Pharma SA

Cerecor Inc

Chronos Therapeutics Ltd

Clera Inc

Corcept Therapeutics Inc

Delpor Inc

DURECT Corp

Eisai Co Ltd

Eli Lilly and Co

Embera NeuroTherapeutics Inc

Fabre-Kramer Pharmaceuticals Inc

FPRT Bio Inc

GlaxoSmithKline Plc

GliaCure Inc

H. Lundbeck AS

Heptares Therapeutics Ltd

Immodulon Therapeutics Ltd

Impel NeuroPharma Inc

Intas Pharmaceuticals Ltd

IntelGenx Corp

Intra-Cellular Therapies Inc

Jiangsu Nhwa Pharmaceutical Corp Ltd

Johnson & Johnson

Karuna Pharmaceuticals Inc

KemPharm Inc

Kissei Pharmaceutical Co Ltd

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

Luye Pharma Group Ltd

Mapi Pharma Ltd

Mapreg SAS

MedinCell SA

Medlab Clinical Ltd

Meta-IQ ApS

Mitsubishi Tanabe Pharma Corp

Navitor Pharmaceuticals Inc

Neuralstem Inc

Neurocrine Biosciences Inc

NeuroNascent Inc

Nippon Chemiphar Co Ltd

Novartis AG

Omeros Corp

Otsuka Holdings Co Ltd

Pfizer Inc

Pherin Pharmaceuticals Inc

Pragma Therapeutics SAS

Protagenic Therapeutics Inc

Relmada Therapeutics Inc

Reviva Pharmaceuticals Inc

Richter Gedeon Nyrt

Sage Therapeutics Inc

Sanofi

Shenox Pharmaceuticals LLC

SK Biopharmaceuticals Co Ltd

Sound Pharmaceuticals Inc

SpringWorks Therapeutics LLC

Sumitomo Chemical Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Syntropharma Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Tonix Pharmaceuticals Holding Corp

Trevena Inc

VistaGen Therapeutics Inc

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 8

2 Introduction 9

2.1 Depression and Anxiety Disorders Report Coverage 9

2.2 Post-Traumatic Stress Disorder (PTSD) - Overview 9

2.3 Obsessive-Compulsive Disorder - Overview 9

2.4 Depression - Overview 9

3 Therapeutics Development 10

3.1 Post-Traumatic Stress Disorder (PTSD) 10

3.2 Obsessive-Compulsive Disorder 17

3.3 Depression 20

4 Therapeutics Assessment 41

4.1 Post-Traumatic Stress Disorder (PTSD) 41

4.2 Obsessive-Compulsive Disorder 49

4.3 Depression 54

5 Companies Involved in Therapeutics Development 68

5.1 Post-Traumatic Stress Disorder (PTSD) 68

5.2 Obsessive-Compulsive Disorder 78

5.3 Depression 80

6 Dormant Projects 122

6.1 Post-Traumatic Stress Disorder (PTSD) 122

6.2 Obsessive-Compulsive Disorder 124

6.3 Depression 125

7 Discontinued Products 141

7.1 Post-Traumatic Stress Disorder (PTSD) 141

7.2 Obsessive-Compulsive Disorder 141

7.3 Depression 142

8 Product Development Milestones 147

8.1 Post-Traumatic Stress Disorder (PTSD) 147

8.2 Obsessive-Compulsive Disorder 156

8.3 Depression 157

9 Appendix 174

9.1 Methodology 174

9.2 Coverage 174

9.3 Secondary Research 174

9.4 Primary Research 174

9.5 Expert Panel Validation 174

9.6 Contact Us 175

9.7 Disclaimer 175

List of Tables

1.1 List of Tables

Table 1: Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) 10

Table 2: Number of Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 12

Table 3: Number of Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 13

Table 4: Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 14

Table 5: Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 16

Table 6: Number of Products under Development for Obsessive-Compulsive Disorder 17

Table 7: Number of Products under Development by Companies, Obsessive-Compulsive Disorder 18

Table 8: Number of Products under Development by Universities/Institutes, Obsessive-Compulsive Disorder 19

Table 9: Products under Development by Companies, Obsessive-Compulsive Disorder 19

Table 10: Products under Development by Universities/Institutes, Obsessive-Compulsive Disorder 19

Table 11: Number of Products under Development for Depression 20

Table 12: Number of Products under Development by Companies, Depression 22

Table 13: Number of Products under Development by Universities/Institutes, Depression 27

Table 14: Products under Development by Companies, Depression 28

Table 15: Products under Development by Universities/Institutes, Depression 39

Table 16: Number of Products by Stage and Target, Post-Traumatic Stress Disorder (PTSD) 42

Table 17: Number of Products by Stage and Mechanism of Action, Post-Traumatic Stress Disorder (PTSD) 45

Table 18: Number of Products by Stage and Route of Administration, Post-Traumatic Stress Disorder (PTSD) 47

Table 19: Number of Products by Stage and Molecule Type, Post-Traumatic Stress Disorder (PTSD) 49

Table 20: Number of Products by Stage and Target, Obsessive-Compulsive Disorder 50

Table 21: Number of Products by Stage and Mechanism of Action, Obsessive-Compulsive Disorder 52

Table 22: Number of Products by Stage and Route of Administration, Obsessive-Compulsive Disorder 53

Table 23: Number of Products by Stage and Molecule Type, Obsessive-Compulsive Disorder 53

Table 24: Number of Products by Stage and Target, Depression 55

Table 25: Number of Products by Stage and Mechanism of Action, Depression 60

Table 26: Number of Products by Stage and Route of Administration, Depression 65

Table 27: Number of Products by Stage and Molecule Type, Depression 67

Table 28: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Actinogen Medical Ltd 68

Table 29: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Addex Therapeutics Ltd 69

Table 30: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Amorsa Therapeutics Inc 69

Table 31: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Aptinyx Inc 69

Table 32: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Azevan Pharmaceuticals Inc 70

Table 33: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Bionomics Ltd 70

Table 34: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Catalyst Pharmaceuticals Inc 71

Table 35: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Chronos Therapeutics Ltd 71

Table 36: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Corcept Therapeutics Inc 72

Table 37: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Eli Lilly and Co 72

Table 38: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Embera NeuroTherapeutics Inc 73

Table 39: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Immodulon Therapeutics Ltd 73

Table 40: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Johnson & Johnson 74

Table 41: Post-Traumatic Stress Disorder (PTSD) – Pipeline by NeuroNascent Inc 74

Table 42: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Omeros Corp 75

Table 43: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Otsuka Holdings Co Ltd 76

Table 44: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Pragma Therapeutics SAS 76

Table 45: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Sanofi 76

Table 46: Post-Traumatic Stress Disorder (PTSD) – Pipeline by SpringWorks Therapeutics LLC 77

Table 47: Post-Traumatic Stress Disorder (PTSD) – Pipeline by Tonix Pharmaceuticals Holding Corp 77

Table 48: Obsessive-Compulsive Disorder – Pipeline by Addex Therapeutics Ltd 78

Table 49: Obsessive-Compulsive Disorder – Pipeline by Amorsa Therapeutics Inc 78

Table 50: Obsessive-Compulsive Disorder – Pipeline by Biohaven Pharmaceutical Holding Company Ltd 79

Table 51: Obsessive-Compulsive Disorder – Pipeline by Omeros Corp 79

List of Figures

1.2 List of Figures

Figure 1: Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) 10

Figure 2: Number of Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 11

Figure 3: Number of Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 13

Figure 4: Number of Products under Development for Obsessive-Compulsive Disorder 17

Figure 5: Number of Products under Development by Companies, Obsessive-Compulsive Disorder 18

Figure 6: Number of Products under Development for Depression 20

Figure 7: Number of Products under Development by Companies, Depression 21

Figure 8: Number of Products under Development by Universities/Institutes, Depression 26

Figure 9: Number of Products by Top 10 Targets, Post-Traumatic Stress Disorder (PTSD) 41

Figure 10: Number of Products by Stage and Top 10 Targets, Post-Traumatic Stress Disorder (PTSD) 41

Figure 11: Number of Products by Top 10 Mechanism of Actions, Post-Traumatic Stress Disorder (PTSD) 43

Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Post-Traumatic Stress Disorder (PTSD) 44

Figure 13: Number of Products by Routes of Administration, Post-Traumatic Stress Disorder (PTSD) 46

Figure 14: Number of Products by Stage and Routes of Administration, Post-Traumatic Stress Disorder (PTSD) 47

Figure 15: Number of Products by Molecule Types, Post-Traumatic Stress Disorder (PTSD) 48

Figure 16: Number of Products by Stage and Molecule Types, Post-Traumatic Stress Disorder (PTSD) 48

Figure 17: Number of Products by Top 10 Targets, Obsessive-Compulsive Disorder 49

Figure 18: Number of Products by Stage and Top 10 Targets, Obsessive-Compulsive Disorder 50

Figure 19: Number of Products by Top 10 Mechanism of Actions, Obsessive-Compulsive Disorder 51

Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, Obsessive-Compulsive Disorder 51

Figure 21: Number of Products by Stage and Routes of Administration, Obsessive-Compulsive Disorder 52

Figure 22: Number of Products by Stage and Top 10 Molecule Types, Obsessive-Compulsive Disorder 53

Figure 23: Number of Products by Top 10 Targets, Depression 54

Figure 24: Number of Products by Stage and Top 10 Targets, Depression 54

Figure 25: Number of Products by Top 10 Mechanism of Actions, Depression 59

Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions, Depression 59

Figure 27: Number of Products by Routes of Administration, Depression 64

Figure 28: Number of Products by Stage and Routes of Administration, Depression 65

Figure 29: Number of Products by Molecule Types, Depression 66

Figure 30: Number of Products by Stage and Molecule Types, Depression 66

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports